ClinicalTrials.gg
RecruitingNCT07630155Updated Nov 12, 2026

Office-Based Ureteroscopy Utilizing a Single Use Digital, Flexible Ureteroscope for Upper Tract Urothelial Carcinoma

An interventional study of Analgesic Agent and Electronic Health Record Review in Renal Pelvis and Ureter Urothelial Carcinoma, sponsored by University of Michigan Rogel Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by University of Michigan Rogel Cancer Center · Not applicable, Interventional, and Diagnostic

How we know

Updated Nov 12, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This clinical trial tests how well office based ureteroscopy utilizing a single use digital, flexible ureteroscope works for the assessment of upper tract urothelial carcinoma. Ureteroscopy is a procedure in which a thin camera called a ureteroscope is used to assess patients with a known or suspected diagnosis of upper tract urothelial carcinoma. Ureteroscopy is traditionally performed in an operating room under general anesthesia. In this study, patients undergo ureteroscopy in the doctor's office using an ultra-thin ureteroscope, which is the narrowest instrument of its kind. Because of its small size, researchers believe this procedure can be completed in the office with minimal discomfort and high patient satisfaction, which may eliminate the risks of general anesthesia and reduce delays to diagnosis. Office based ureteroscopy utilizing a single use digital, flexible ureteroscope may be effective for the assessment of upper tract urothelial carcinoma.

02

Conditions studied

  • Renal Pelvis and Ureter Urothelial Carcinoma
03

In context

Lead sponsor

University of Michigan Rogel Cancer Center is the lead sponsor of 325 studies on the registry; 49 are open to participants now.

Of its 46 completed or terminated interventional studies of FDA-regulated products, 31 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged ≥ 18 year. Both sexes are included to reflect the patient population with upper tract urothelial carcinoma (UTUC) already being followed at the University of Michigan and allow exploration of potential differences in tolerability of awake ureteroscopy based on sex
  • History of endoscopically managed UTUC at any time, or a suspected diagnosis of UTUC based on pre-procedure imaging, and is already planned for office-based ureteroscopic assessment
  • Ability and willingness to complete and adhere to survey questions and responses throughout study duration

Exclusion criteria

Exclusion Criteria:

  • Known ureteral strictures
  • Active urinary tract infection
  • Need for general anesthesia due to patient or procedural factors
  • History of inability to tolerate ureteroscopy under local anesthetic
  • Anticipated need for laser ablation during the surveillance procedure
  • Pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Diagnostic (in office ureteroscopy)

    Patients receive lidocaine jelly intraurethrally for local anesthesia. Patients then undergo ureteroscopy using the 6.3 Fr single use digital ureteroscope. Per standard of care practice, patients receive pain medication PO on an as needed basis prior to and immediately after the procedure.

    Drug: Analgesic Agent · Other: Electronic Health Record Review · Drug: Lidocaine Topical · Device: Medical Device Usage and Evaluation · Other: Survey Administration · Procedure: Ureteroscopy

Interventions

  • DrugAnalgesicsStudies of AnalgesicsAnalgesics pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given PO

    Also known as: analgesic, Analgesic Drugs, Analgesics, Anodynes, Antinociceptive Agents, Pain-relief Medication

  • OtherElectronic Health Record Review

    Ancillary studies

  • Given intraurethrally

  • DeviceMedical Device Usage and Evaluation

    Undergo ureteroscopy using 6.3 Fr single use digital ureteroscope

  • OtherSurvey Administration

    Ancillary studies

  • ProcedureUreteroscopy

    Undergo ureteroscopy

06

What researchers measure

Primary outcomes

  1. Success rate

    Defined as the ability to successfully perform and complete upper and lower tract surveillance with the 6.3 French ureteroscope in an office setting. A study-wide successful outcome will be defined as a success rate of 70%. The success rate will be reported as the count and proportion of participants with a successful outcome out of the number of enrolled participants. The corresponding 95% binomial Clopper-Pearson confidence interval will be reported.

    Time frame: On day of procedure

Secondary outcomes

  1. Pain

    Assessed by intra- and peri-procedure patient reported outcomes with the visual analogue scale pain score, as well as the Patient-Reported Outcomes Measurement Information System Pain Interference and Intensity score. Will be summarized and displayed graphically with means, standard deviations and/or quartiles.

    Time frame: From baseline up to 7-10 days post procedure

  2. Satisfaction

    Assessed by the International Consultation on Incontinence-Satisfaction. Will be summarized and displayed graphically with means, standard deviations and/or quartiles.

    Time frame: At 7-10 days post procedure

  3. Unplanned healthcare use

    Will measure unplanned healthcare utilization including electronic messages, phone calls, lab and imaging tests, emergency department visits, hospitalizations, and secondary interventions. These will be reported as counts of events and counts of participants with corresponding proportions of enrolled participants.

    Time frame: From baseline up to 30 days post procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2026 (actual). Primary completion is estimated for Oct 2027, 12 months after the start.

Start moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, last on Nov 12, 2026.

Primary completion moved twice since we started tracking on Sep 25, 2026: Aug 2027 → Oct 2027, last on Nov 12, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Aug 2027 → Oct 2027, last on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2026
First posted
Jun 5, 2026
StartActual
Oct 26, 2026was Aug 2026
Primary completionEst.
Oct 2027was Aug 2027
CompletionEst.
Oct 2027was Aug 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 2026→Oct 26, 2026 (actual)
moved 2 times, Oct 15, 2026 – Nov 12, 2026
Primary completion
Aug 2027→Oct 2027
moved 2 times, Oct 15, 2026 – Nov 12, 2026
Study completion
Aug 2027→Oct 2027
moved 2 times, Oct 15, 2026 – Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    Start date Dec 2026→Oct 26, 2026 (now actual)
    Primary completion Dec 2027→Oct 2027
    Study completion Dec 2027→Oct 2027
    + 2 other changes: identifiers and verification date
  2. Oct 15, 2026
    Start date Aug 2026→Dec 2026
    Primary completion Aug 2027→Dec 2027
    Study completion Aug 2027→Dec 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07630155
Collaborators
Shenzhen HugeMed Medical Technical Development
Responsible party
Sponsor
First posted
Jun 5, 2026
Start date
Oct 26, 2026
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Michael Uy, MD
Contact
Uymichae@med.umich.edu
734-936-7030
Khurshid Ghani, MD
principal investigator · University of Michigan Rogel Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Analgesics · Lidocaine Topical

Start the discussion